Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance

  • Authors:
    • Giuseppina Improta
    • Angela Pettinato
    • Stefania Gieri
    • Giuseppa Scandurra
    • Wojciech Skovrider‑Ruminski
    • Estrid Høgdall
    • Filippo Fraggetta
  • View Affiliations

  • Published online on: November 5, 2015     https://doi.org/10.3892/ol.2015.3863
  • Pages: 393-398
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Epidermal growth factor receptor (EGFR) plays a significant role in non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer worldwide. Therefore, EGFR may be a useful molecular target for personalized therapy utilizing tyrosine kinase inhibitors (TKIs). Somatic activating EGFR mutations may be used to identify tumors sensitive to the effects of small‑molecule EGFR‑TKIs (gefitinib and erlotinib), and alternative, less frequently observed mutations, including the majority of mutations identified within exon 20, may be associated with a lack of response to TKIs. However, due to the comparative rarity of EGFR exon 20 mutations, clinical information concerning the association between EGFR exon 20 mutations and responsiveness to TKIs has been limited within the relevant literature, particularly for certain rare mutations, including p.S768I. The current study reports the case of a patient with NSCLC harboring a p.S768I mutation in the EGFR gene [a substitution at codon 768 of exon 20 (c.2303G>T, p.S768I)], as well as a mutation at codon 719, exon 18 (p.G719A). The relevant literature concerning this rare EGFR somatic mutation is also reviewed.
View Figures
View References

Related Articles

Journal Cover

January-2016
Volume 11 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Improta G, Pettinato A, Gieri S, Scandurra G, Skovrider‑Ruminski W, Høgdall E and Fraggetta F: Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance. Oncol Lett 11: 393-398, 2016
APA
Improta, G., Pettinato, A., Gieri, S., Scandurra, G., Skovrider‑Ruminski, W., Høgdall, E., & Fraggetta, F. (2016). Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance. Oncology Letters, 11, 393-398. https://doi.org/10.3892/ol.2015.3863
MLA
Improta, G., Pettinato, A., Gieri, S., Scandurra, G., Skovrider‑Ruminski, W., Høgdall, E., Fraggetta, F."Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance". Oncology Letters 11.1 (2016): 393-398.
Chicago
Improta, G., Pettinato, A., Gieri, S., Scandurra, G., Skovrider‑Ruminski, W., Høgdall, E., Fraggetta, F."Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance". Oncology Letters 11, no. 1 (2016): 393-398. https://doi.org/10.3892/ol.2015.3863